Long Duration of Immunotherapy in a STK11 Mutated/KRAS Wild-type Non-small Cell Lung Cancer Patient
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a mutation.
An J, Yan M, Yu N, Chennamadhavuni A, Furqan M, Mott S Transl Lung Cancer Res. 2021; 10(8):3608-3615.
PMID: 34584860 PMC: 8435393. DOI: 10.21037/tlcr-21-177.
The Importance of / Assessment in Non-Small Cell Lung Carcinomas.
Mograbi B, Heeke S, Hofman P Diagnostics (Basel). 2021; 11(2).
PMID: 33572782 PMC: 7912095. DOI: 10.3390/diagnostics11020196.